Vivek Kumar

Jump to

Investor Camp: Here's a glimpse at Chandigarh Edition

Watch Chandigarh Edition of Investor Camp where CNBC-TV18's Anuj Singhal & Reema Tendulkar discussed market and specific stocks at length with experts like Ashwani Gujral of ashwanigujral.com, Prakash Diwan of prakashdiwan.in and Vivek Kumar, Principal Economist at Yes Bank.
Dahej unit to boost company financials: Insecticides India

Sandeep Aggarwal, CFO of Insecticides India says the capacity utilisation from the Dahej unit would be around 75 percent and expect the unit to add to the financials of the company in a big way.
Buy Ranbaxy Labs, target of Rs 620-630: Vivek Kumar

Vivek Kumar, SBI Cap Securities advice traders to buy Ranbaxy Labs for target of Rs 620-630.
Ranbaxy delivers strong nos; SBI Cap Sec advises to buy

In an interview to CNBC-TV18, Vivek Kumar, SBI Cap Securities spoke about Ranbaxy's results and his outlook going forward.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Vivek Kumar

Investor Camp: Here's a glimpse at Chandigarh Edition

Dahej unit to boost company financials: Insecticides India

Buy Ranbaxy Labs, target of Rs 620-630: Vivek Kumar

Ranbaxy delivers strong nos; SBI Cap Sec advises to buy